Document Detail

Effect of calcium channel antagonists on susceptibility to sudden cardiac death: protection from ventricular fibrillation.
MedLine Citation:
PMID:  2467981     Owner:  NLM     Status:  MEDLINE    
The effects of calcium channel antagonists and an agonist on susceptibility to ventricular fibrillation were investigated using chronically instrumented dogs with a healed anterior wall myocardial infarction. Three to 4 weeks after the infarction, a 2-min coronary occlusion was initiated during the last minute of exercise and continued for 1 min after cessation of exercise. Twenty-two dogs developed ventricular fibrillation (susceptible) whereas the remaining 14 animals did not (resistant) during this exercise plus ischemia test. The exercise plus ischemia test was repeated in the susceptible dogs after the following treatments: verapamil (n = 17, 250 micrograms/kg), nifedipine (n = 9, 10 and 100 micrograms/kg) and magnesium sulfate (n = 9, 100 mg/kg). Verapamil prevented ventricular fibrillation in all dogs whereas the high dose of nifedipine protected eight of nine animals; the low dose of nifedipine protected one of nine animals and magnesium sulfate protected seven of nine dogs. Finally, the calcium channel agonist Bay K8644 (n = 9, 30 micrograms/kg) was given to resistant animals. All resistant dogs developed ventricular fibrillation when the exercise plus ischemia test was repeated after Bay K8644. These data suggest that calcium entry may play a critical role in the development of arrhythmias during ischemia, with increased calcium entry provoking arrhythmias and calcium entry blockade preventing the lethal events.
G E Billman
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  248     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  1989 Mar 
Date Detail:
Created Date:  1989-05-12     Completed Date:  1989-05-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1334-42     Citation Subset:  IM    
Department of Physiology, The Ohio State University, Columbus.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
Calcium / physiology
Calcium Channel Blockers / pharmacology*,  therapeutic use
Death, Sudden*
Hemodynamics / drug effects
Magnesium Sulfate / pharmacology
Nifedipine / pharmacology
Ventricular Fibrillation / prevention & control*
Verapamil / pharmacology
Grant Support
Reg. No./Substance:
0/Calcium Channel Blockers; 21829-25-4/Nifedipine; 52-53-9/Verapamil; 71145-03-4/3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; 7440-70-2/Calcium; 7487-88-9/Magnesium Sulfate
Erratum In:
J Pharmacol Exp Ther 1990 Dec;255(3):1407

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs.
Next Document:  Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated.